Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

618 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of bisphosphonates in cancer patients.
Body JJ, Coleman RE, Piccart M. Body JJ, et al. Among authors: piccart m. Cancer Treat Rev. 1996 Jul;22(4):265-87. doi: 10.1016/s0305-7372(96)90020-1. Cancer Treat Rev. 1996. PMID: 9025784 Review. No abstract available.
Ureteral obstruction in patients with breast cancer.
Recloux P, Weiser M, Piccart M, Sculier JP. Recloux P, et al. Among authors: piccart m. Cancer. 1988 May 1;61(9):1904-7. doi: 10.1002/1097-0142(19880501)61:9<1904::aid-cncr2820610930>3.0.co;2-1. Cancer. 1988. PMID: 3355980
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M. Piccart MJ, et al. J Clin Oncol. 1997 Sep;15(9):3149-55. doi: 10.1200/JCO.1997.15.9.3149. J Clin Oncol. 1997. PMID: 9294478 Clinical Trial.
New cytotoxic agents.
Piccart M. Piccart M. Cancer Treat Rev. 1997 Jul;23 Suppl 1:S59-67. doi: 10.1016/s0305-7372(97)90008-6. Cancer Treat Rev. 1997. PMID: 9377603 Review. No abstract available.
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M. Paridaens R, et al. Among authors: piccart m. J Clin Oncol. 2000 Feb;18(4):724-33. doi: 10.1200/JCO.2000.18.4.724. J Clin Oncol. 2000. PMID: 10673513 Clinical Trial.
EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancer.
Hamilton A, Roy JA, Beex L, Piccart M, Mauriac L, Coleman R, Paridaens R, Boes GH, van Vreckem A, Palmer P, Klijn J. Hamilton A, et al. Among authors: piccart m. Breast Cancer Res Treat. 2000 Mar;60(2):181-8. doi: 10.1023/a:1006398518037. Breast Cancer Res Treat. 2000. PMID: 10845281 Clinical Trial.
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ. Biganzoli L, et al. Among authors: piccart mj. J Clin Oncol. 2002 Jul 15;20(14):3114-21. doi: 10.1200/JCO.2002.11.005. J Clin Oncol. 2002. PMID: 12118025 Clinical Trial.
618 results